Xenon in the treatment of panic disorder: an open label study

BACKGROUND: Current treatments of panic disorder (PD) are limited by adverse effects, poor efficacy, and need for chronic administration. The established safety profile of subanesthetic concentrations of xenon gas, which is known to act as a glutamate subtype NMDA receptor antagonist, coupled with p...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobrovolsky, Alexander, Ichim, Thomas E., Ma, Daqing, Kesari, Santosh, Bogin, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470223/
https://www.ncbi.nlm.nih.gov/pubmed/28610592
http://dx.doi.org/10.1186/s12967-017-1237-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470223/
https://www.ncbi.nlm.nih.gov/pubmed/28610592
http://dx.doi.org/10.1186/s12967-017-1237-1

Ejemplares similares